MERSANA THERAPEUTICS INC
Pagina dedicata companiei MERSANA THERAPEUTICS INC listata cu simbolul US.MRSN
Descriere companie[edit | ]
Mersana Therapeutics, Inc. (http://www.mersana.com/) is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.
Grafic actiuni companie[edit | ]